

## Special Issue

# STAT3 in Carcinogenesis: Update from 1993 to Present

### Message from the Guest Editors

Signal Transducer and Activator of Transcription 3 (STAT3) is a 30-year-old protein. As a pro-inflammatory transcription factor, signal transducer, and transcription activator, it was identified in 1994. Its activation is crucial in various *diseases as chronic inflammation, cardiovascular and metabolic disorders*, and cancer. In fact, a lot of scientific publications assessed the involvement of STAT3, through both its canonical and non-canonical pathways. Its multifaceted activities are mainly ensured by post-translational modifications such as phosphorylation, acetylation, glutathionylation, etc. This Special Issue aims to review all the scientific advances on the STAT3 protein achieved in the past 30 years focusing on current and future research on the role of the STAT3 protein, its potential inhibitors or modulators in both carcinogenesis and chemoresistance phenomenon. We hope that researchers in the field contribute with research articles, review articles, innovative hypotheses, or commentaries on STAT3's activities and regulations.

---

### Guest Editors

Dr. Donatella Romaniello

Dr. Ilaria Marrocco

Dr. Margherita Eufemi

---

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/175942](https://mdpi.com/si/175942)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).